An open-label study to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosed with biopsy-proven IgA nephropathy (IgAN) - completed of 9 months of treatment of Tarpeyo 16mg twice a day (we start screening participants after 7 1/2 months of Tarpeyo treatment so we have enough time to complete all requirements before entering the study). Please contact the study team as early as possible. - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- treated with systemic immunosuppressants including glucocorticosteroids other than Tarpeyo during treatment of Tarpeyo - current or planned dialysis - undergone kidney transplant - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:
Drug: TARPEYO®
Conditions:
Kidney, Prostate & Urinary
Keywords:
Berger's Disease, Clinics and Surgery Center (CSC), IgA Nephropathy, IgAN

More Information

Description: This study is about finding out if the study drug, TARPEYO®, can be taken for a longer time (2 years) than the current recommended 9 months, to better help people with primary IgA nephropathy (IgAN).
Study Contact: Nattawat Klomjit - klomj001@umn.edu
Principal Investigator: Nattawat Klomjit
Phase: PHASE4
IRB Number: STUDY00024442